A case of metastasectomy following multiple courses of radionuclide therapy for distant metastatic pheochromocytoma.

Authors

Naoki Wada, Satoshi Kawata, Yoshinari Obata, Yoshito Tomimaru, Junji Kozawa, Iichiro Shimomura

Published in

JCEM case reports. Volume 4. Issue 11. Pages luag307. Epub Oct 05, 2026.

Abstract

Pheochromocytomas and paragangliomas (PPGLs) are neuroendocrine tumors derived from chromaffin cells that produce catecholamines. The primary treatment for PPGLs is surgical resection, and even in cases with distant metastases, metastasectomy may be considered. Other therapeutic options for distant metastatic disease include radionuclide therapy, such as ¹³¹I-metaiodobenzylguanidine (MIBG) and ¹⁷⁷Lu-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-(Tyr³)-octreotate (DOTATATE). However, clear evidence is lacking regarding which patients with distant metastases are the best candidates for metastasectomy or radionuclide therapy. Herein, we report a case of a 58-year-old man who underwent resection of a left pheochromocytoma 10 years prior and was admitted for treatment of recurrent metastases to the liver and peritoneum. Sequential ¹³¹I-MIBG and ¹⁷⁷Lu-DOTATATE therapies were administered, which contributed to disease control and reduction of catecholamine levels but did not achieve a complete response. Subsequently, all metastatic lesions were successfully resected, leading to normalization of catecholamine secretion. This case suggests that metastasectomy may be preferable to radionuclide therapy in carefully selected patients with limited, resectable metastatic disease, despite the presence of distant and multiple metastases. Furthermore, it highlights the importance of periodic reassessment of resectability in patients with distant metastases, even when radionuclide therapy is initially selected, and consideration of metastasectomy once complete resection becomes feasible.

PMID:
42831206
Bibliographic data and abstract were imported from PubMed on 05 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.